Nicolas  Duforet-Frebourg Duforet-Frebourg

Dr. Nicolas Duforet-Frebourg Duforet-Frebourg


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2022 in Cancers
Verified
Journal Article
Open access
PDF file
PPP. Pujol
P. Pujol
KYKevin Yauy
Kevin Yauy
CAcoffy amandine
coffy amandine
NDNicolas Duforet-Frebourg Duforet-Frebourg
Nicolas Duforet-Frebourg Duforet-Frebourg
SGSana Gabteni
Sana Gabteni
NPNicolas Philippe
Nicolas Philippe
Background: Poly(ADP-ribose) polymerase 1 inhibitor (PARPi) agents can improve progression-free survival of patients with breast cancer who carry a germline BRCA1 or BRCA2 pathogenic or likely pathogenic variant (gBRCA) in both the metastatic and adjuvant setting. Therefore, we need to reassess the frequency of gBRCA1 and gBRCA2 in order to redefine the criteria for women and tumor phenotype that should be tested. Objective: We studied the relative distribution of gBRCA1 and gBRCA2 in unselected populations of women with breast cancer and in unaffected individuals. We also analyzed the proportion of estrogen receptor (ER)-positive (ER+) tumors in unselected breast cancer patients with gBRCA. Design: We performed a meta-analysis of studies of unselected breast cancer that analyzed the relative contribution of gBRCA1 versus gBRCA2 among unselected breast cancer cases in gBRCA carriers. We then performed a meta-analysis of gBRCA carriage in unaffected individuals from genome-wide population studies, the gnomAD databank, and case–control studies. Results: The BRCA2 gene was involved in 54% of breast cancer cases in unselected patients with gBRCA (n = 108,699) and 60% of unaffected individuals (n = 238,973) as compared with 38% of the largest gBRCA family cohort (n = 29,700). The meta-analysis showed that 1.66% (95% CI 1.08–2.54) and 1.71% (95% CI 1.33–2.2) of unselected breast cancer patients carried gBRCA1 and gBRCA2, respectively. In a population of unaffected individuals, the frequency of heterozygosity for gBRCA1 and gBRCA2 was estimated at 1/434 and 1/288, respectively. Nearly 0.5% of unaffected individuals in the studied populations carried a gBRCA. Carriage of a gBRCA was 2.5% for patients with ER+ tumors (95% CI 1.5–4.1) and 5.7% (95% CI 5.1–6.2) for those with ER- tumors. Overall, 58% of breast tumors occurring in women carrying a gBRCA were ER+ (n = 86,870). Conclusions: This meta-analysis showed that gBRCA2 carriage is predominant in unselected breast cancer patients and unaffected individuals. ER+ tumors among women with gBRCA-related breast cancer are predominant and have been underestimated. Because PARPi agents improve progression-free survival with ER+ gBRCA breast cancer in most clinical trials, breast cancer should be considered, regardless of ER status, for BRCA1/2 screening for therapeutic purposes.

5 February 2025 in medRxiv
Verified
Preprint
Open access
PDF file
JRJiri Ruzicka
Jiri Ruzicka
JRJean-Marie Ravel
Jean-Marie Ravel
JAJérôme Audoux
Jérôme Audoux
ABAlexandre Boulat
Alexandre Boulat
JTJulien Thévenon
Julien Thévenon
LMLaurent Mesnard
Laurent Mesnard
The growing use of genomic sequencing to diagnose hereditary diseases has increased the interpretive workload for clinical laboratories. Efficient methods are needed to maximize diagnostic yield without overwhelming resources. We developed DiagAI, an integrative machine-learning system trained to prioritize and sort causal variants in rare diseases. DiagAI integrates Universal Pathogenicity Predictor (UP 2 ), a machine-learning model trained to predict ACMG pathogenicity classes, PhenoGenius to match genotype-phenotype interactions and expert features such as inheritance and variant quality. We retrospectively analyzed 196 diagnosed exomes from a nephrology cohort. To benchmark UP 2 ’s performance, we evaluated the ranking of 62 causal missense variants. UP 2 ranked variants most effectively beyond shortlist sizes of 10 and identified pathogenic variants missed by AlphaMissense. DiagAI identified 94.9% of causal variants in diagnostic exomes with HPO terms, compared to 90.8% without, with median shortlist sizes of 12 and 9 variants, respectively. With HPO terms, 74% of top-ranked variants were diagnostic, versus 42% without, outperforming Exomiser and AI-MARRVEL. DiagAI produces accurate shortlists that streamline variant interpretation, offering a scalable solution for growing diagnostic volumes.

Verified
Journal Article
Open access
PDF file
JRJiri Ruzicka
Jiri Ruzicka
JRJean-Marie Ravel
Jean-Marie Ravel
JAJérôme Audoux
Jérôme Audoux
ABAlexandre Boulat
Alexandre Boulat
JTJulien Thévenon
Julien Thévenon
LMLaurent Mesnard
Laurent Mesnard
Genome and exome sequencing have become central to diagnosing rare hereditary diseases, but each test returns thousands of variants that a clinical scientist must review by hand to find the one responsible for the patient’s condition. This manual interpretation is the main bottleneck in clinical genomics. To reduce it, we developed DiagAI, a machine-learning system that ranks the variants found in a patient and returns a short list of the most likely causal candidates. DiagAI combines three sources of evidence: a pathogenicity score from the Universal Pathogenicity Predictor (UP2), a model we trained to estimate how damaging a variant is on the five-tier scale of the American College of Medical Genetics and Genomics (ACMG); a phenotype-matching score from PhenoGenius, which weighs how well a gene’s known clinical features match the patient’s symptoms (encoded as Human Phenotype Ontology, or HPO, terms); and expert rules covering inheritance pattern and sequencing quality. We evaluated DiagAI on 966 exomes from adults investigated for kidney disease of unknown cause, of which 196 had a confirmed genetic diagnosis. We first tested UP2 on its own by ranking 62 confirmed disease-causing missense variants that were absent from its training data: UP2 placed the causal variant within the top 100 candidates in 87% of cases, compared with 61% for the widely used tool REVEL. Across the 196 diagnosed exomes, the full DiagAI shortlist contained the causal variant in 94.9% of cases when the patient’s symptoms were provided and in 90.8% when they were not, with a typical shortlist of about 10 variants. When symptoms were provided, the single top-ranked variant was the correct diagnosis in 74% of cases, versus 42% without symptoms, exceeding the performance of the established tools Exomiser and AI-MARRVEL on the same cohort. DiagAI produces compact, accurate shortlists that can reduce the manual interpretation workload as diagnostic sequencing volumes continue to grow.